Immunic Inc (IMUX) Stock Price, Quote & News

Company Profile

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restor...

Industry: Biotechnology

Sector: Healthcare

Phone: 332 255 9818

Website: imux.com

Address:

1200 Avenue of the Americas, Suite 200, New York, United States

Jw242 Sep. 5 at 2:28 PM

$IMUX happy Friday my true longs here. Will will make it one day

2 · Reply

Mvvh1987 Sep. 5 at 8:12 AM

$IMUX saw something nice on LinkedIn. Immunic just adopted the CARA Life Sciences Platform to handle regulatory operations & submissions. Why does this matter? 👇 It streamlines filings, speeds up submission cycles, and ensures compliance with FDA/EMA. In plain words → IMUX is building the infrastructure needed to get drugs to market faster.

1 · Reply

ohmikeyoh Sep. 4 at 8:17 PM

$IMUX Added more today. Look at the charts this beauty swings up and down consistently. Great swing trade short term potential if thats your thing. Long term potential? Sky is the limit assuming phase 3 is a success in late 2026. Only risk is near term dilution within the next 1-2 Quarters. -Insiders were buying at around these levels (multiple insiders including CEO, CFO and COO!) How bullish is that -Accumulation by funds focused on biotech -Heavily beaten down the last month -Decently shorted. High short squeeze potential. Great swing setup -Company is exploring "potential licensing, financing or partnership opportunities" A deal for one of its assets (presumably an early stage drug) would be the catalyst to make this rip in the near term future (talking months) not days :) Average of 0.72 will continue to add if it drops

5 · Reply

coujatrader Sep. 4 at 8:07 PM

$IMUX will this ever

0 · Reply

cbowers8171 Sep. 4 at 4:03 PM

$IMUX confidence will return for this long play.

0 · Reply

master_yan Sep. 4 at 3:23 PM

$IMUX

0 · Reply

lydia1972 Sep. 4 at 2:52 PM

$IMUX Eigentlich ohne Worte das wir so tief stehen. Wenn man die Historie sieht

2 · Reply

Jw242 Sep. 4 at 1:36 PM

$IMUX when will the pain 🚂 end?!?

3 · Reply

Bulltrader988 Sep. 4 at 11:54 AM

$IMUX "...September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Jason Tardio, President and Chief Operating Officer of Immunic, will present a company overview. The on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright September 17-19: 2025 Leerink Partners Biopharma Summit. Dr. Vitt will participate in this summit in Healdsburg, CA. September 24-26: 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members of Immunic's management, medical, clinical and preclinical teams will attend this conference in Barcelona, Spain. Data on Immunic's orally available lead-asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) will be presented in an oral presentation and four poster presentations, including one late-breaking poster. Additionally, the team will be available throughout the event at booth #B37.." 👃👀 https://www.stocktitan.net/news/IMUX/immunic-to-participate-in-investor-and-scientific-conferences-in-anumibd6xvo0.html

0 · Reply

Mvvh1987 Sep. 4 at 11:23 AM

$IMUX Big September ahead: 📅 Sept 8–10 → H.C. Wainwright (NY) 📅 Sept 17–19 → Leerink Biopharma Summit (CA) 📅 Sept 24–26 → ECTRIMS 2025 (Barcelona) = 🔑 🔥 Oral presentation on CALLIPER progressive MS data (Cleveland Clinic’s Dr. Fox presenting) 🔥 Late-breaking poster in Primary Progressive MS (huge market, only Roche competes here) 🔥 3 more posters (neuroprotection + long-term safety/tolerability)

0 · Reply

Immunic to Participate in Investor and Scientific Conferences in September

Aug 7, 2025, 6:30 AM EDT - 4 weeks ago

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 24, 2025, 6:30 AM EDT - 2 months ago

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Jun 9, 2025, 5:51 PM EDT - 3 months ago

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Jun 5, 2025, 6:30 AM EDT - 3 months ago

Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS

Jun 3, 2025, 4:01 PM EDT - 3 months ago

Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering

Jun 2, 2025, 6:30 AM EDT - 3 months ago

Immunic to Participate in Investor, Scientific and Industry Conferences in June

May 29, 2025, 7:05 AM EDT - 3 months ago

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

May 28, 2025, 4:02 PM EDT - 3 months ago

Immunic, Inc. Announces Proposed Public Offering

May 2, 2025, 6:30 AM EDT - 4 months ago

Immunic to Participate in Scientific and Industry Conferences in May

Apr 30, 2025, 7:30 AM EDT - 4 months ago

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

Apr 28, 2025, 2:09 AM EDT - 4 months ago

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Apr 10, 2025, 1:00 PM EDT - 5 months ago

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 9, 2025, 8:10 AM EDT - 5 months ago

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Apr 1, 2025, 6:30 AM EDT - 5 months ago

Immunic, Inc. to Participate in Scientific and Industry Conferences in April

Mar 3, 2025, 6:30 AM EST - 6 months ago

Immunic to Participate in Scientific and Investor Conferences in March

Feb 26, 2025, 6:30 AM EST - 6 months ago

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

Feb 20, 2025, 7:30 AM EST - 7 months ago

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Feb 4, 2025, 6:30 AM EST - 7 months ago

Immunic to Participate in Investor and Scientific Conferences in February

Jan 7, 2025, 6:30 AM EST - 8 months ago

Immunic Highlights 2024 Accomplishments and Upcoming Milestones

Nov 26, 2024, 6:30 AM EST - 10 months ago

Immunic, Inc. to Participate in Investor Conference in December

Nov 13, 2024, 6:30 AM EST - 10 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology

Nov 9, 2024, 8:37 AM EST - 10 months ago

Immunic, Inc. (IMUX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:30 AM EST - 10 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 31, 2024, 6:30 AM EDT - 11 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Oct 29, 2024, 6:30 AM EDT - 11 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November

Oct 22, 2024, 6:30 AM EDT - 11 months ago

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Sep 18, 2024, 6:30 AM EDT - 1 year ago

Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis

Sep 4, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome

Aug 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September

Aug 9, 2024, 6:55 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Jul 24, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec

Jul 9, 2024, 6:30 AM EDT - 1 year ago

Immunic Appoints Jason Tardio as Chief Operating Officer and President

May 28, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Industry and Scientific Conferences in June

May 8, 2024, 2:20 PM EDT - 1 year ago

Immunic, Inc. (IMUX) Q1 2024 Earnings Call Transcript

May 8, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024, 6:30 AM EDT - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in May

May 1, 2024, 6:30 AM EDT - 1 year ago

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

Apr 30, 2024, 6:30 AM EDT - 1 year ago

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

Apr 4, 2024, 6:30 AM EDT - 1 year ago

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

Mar 20, 2024, 6:30 AM EDT - 1 year ago

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Mar 7, 2024, 6:30 AM EST - 1 year ago

Immunic to Participate in Investor and Scientific Conferences in March

Feb 29, 2024, 6:30 AM EST - 1 year ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

Feb 22, 2024, 3:38 PM EST - 1 year ago

Immunic, Inc. (IMUX) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Feb 15, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

Jan 5, 2024, 6:35 AM EST - 1 year ago

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Jan 5, 2024, 6:30 AM EST - 1 year ago

Immunic, Inc. Announces Private Placement of up to $240 Million

Jw242 Sep. 5 at 2:28 PM

$IMUX happy Friday my true longs here. Will will make it one day

2 · Reply

Mvvh1987 Sep. 5 at 8:12 AM

1 · Reply

ohmikeyoh Sep. 4 at 8:17 PM

5 · Reply

coujatrader Sep. 4 at 8:07 PM

$IMUX will this ever

0 · Reply

cbowers8171 Sep. 4 at 4:03 PM

$IMUX confidence will return for this long play.

0 · Reply

master_yan Sep. 4 at 3:23 PM

$IMUX

0 · Reply

lydia1972 Sep. 4 at 2:52 PM

$IMUX Eigentlich ohne Worte das wir so tief stehen. Wenn man die Historie sieht

2 · Reply

Jw242 Sep. 4 at 1:36 PM

$IMUX when will the pain 🚂 end?!?

3 · Reply

Bulltrader988 Sep. 4 at 11:54 AM

0 · Reply

Mvvh1987 Sep. 4 at 11:23 AM

0 · Reply

master_yan Sep. 3 at 10:57 PM

$IMUX

1 · Reply

AitorMenta Sep. 3 at 9:09 PM

$IMUX good end, good volume. We have attention yet

0 · Reply

GeauxTig Sep. 3 at 7:26 PM

$IMUX 188 k share trade at .78! Who sells at this level?

0 · Reply

Cattitude Sep. 3 at 4:31 PM

$IMUX yikes 😳 we heading for splittsville?

0 · Reply

Starflash Sep. 3 at 2:50 PM

$IMUX What comes down, must come up.

1 · Reply

Jw242 Sep. 3 at 2:34 PM

$IMUX thanks Vitt

1 · Reply

King_of_Bio Sep. 3 at 1:25 PM

$IMUX

0 · Reply

Jw242 Sep. 2 at 4:46 PM

$IMUX bye bye

2 · Reply

Jw242 Sep. 2 at 1:47 PM

$IMUX said I was done buying but can’t stop at these levels

0 · Reply

Jw242 Sep. 2 at 12:49 PM

$IMUX maybe biotech is a safe haven while the orange man market sharts…..

1 · Reply

cbowers8171 Sep. 2 at 12:12 AM

$IMUX can’t wait for the genius October or November plan… the reverse split. 🎉 Take an 82¢ stock, move the decimal, and pretend it’s progress. Nothing fixed, just fewer crumbs to fight over. Yay

0 · Reply

Nolimit90 Aug. 29 at 10:09 PM

$IMUX this shouldn’t be dropping and I’m surprised this has 12 thousand something watchers and doesn’t have much input from anyone

2 · Reply

Market Cap	75.07M
Revenue (ttm)	0.00
Net Income (ttm)	-100.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,053,800
Avg Vol	1,151,314
Day's Range	N/A - N/A
Shares Out	98.65M
Stochastic %K	10%
Beta	1.44
Analysts	Strong Sell
Price Target	$7.47